Jan 05, 2022 / 10:00PM GMT
Operator
Good afternoon, and welcome to the Sutro Biopharma KOL Conference Call to discuss Phase I interim dose expansion clinical data for STRO-002 for treatment of advanced ovarian cancer. (Operator Instructions) Please be advised that the call is being recorded at the company's request and will be available on the company's website for at least 30 days.
Now at this time, I would like to turn the call over to Ed Albini, Chief Financial Officer at Sutro Biopharma. Sir, please go ahead.
Edward C. Albini - Sutro Biopharma, Inc. - CFO & Secretary
Thank you, operator. Good afternoon, everyone, and thank you for joining us. With me on the call are Bill Newell, Chief Executive Officer; Dr. Arturo Molina, Chief Medical Officer; Dr. Trevor Hallam, President of Research and Chief Scientific Officer; and we also welcome on the line Dr. R. Wendel Naumann of the Levine Cancer Institute at Atrium Health.
This afternoon, we issued a news release that you can find on our website at www.sutrobio.com
Sutro Biopharma Inc to Discuss Interim Data on the STRO-002 Phase 1 Dose-Expansion Call Transcript
Jan 06, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers